SammyJo
SammyJo
Sex: F
Data Quality: 1 star
MS: 17 yrs
Type: Secondary Progressive
Sensation: None
Overall: None
Cognition: none
Vision: mild
Speech: none
Swallowing: none
Upper limb: none
Walking: moderate
SammyJo
Female, 47 years
Edmonds, WA
Primary Condition
MS
Type
Secondary Progressive
First symptom
12/94
Diagnosis
07/95
See more

Treatment charts require Flash. If you have problems installing Flash, visit the FAQ for help.

Get Adobe Flash player

SammyJo's Solu-Medrol is for:

  • Other
  • MS

SammyJo has not reported any side effects for Solu-Medrol.

SammyJo's Solu-Medrol History (Stopped)
Solu-Medrol (methylprednisolone)
500 mg Daily Jul 20 - 25, 1995
500 mg Daily Oct 20 - 25, 1995
500 mg Daily Feb 19 - 24, 1996
500 mg Daily Dec 21 - 26, 1996
500 mg Daily Jul 15 - 20, 1997
500 mg Daily Dec 15 - 20, 1997
500 mg Daily Apr 15 - 20, 1998
500 mg Daily Nov 30 - Dec 04, 1998
Daily Aug 01 - 03, 2003
500 mg Daily Sep 01 - 03, 2003
500 mg Daily Oct 01 - 03, 2003
500 mg Daily Nov 01 - 03, 2003
500 mg Daily Dec 01 - 03, 2003
Stopped Course of treatment ended Jul 25, 1995
Stopped Course of treatment ended Oct 25, 1995
Stopped Course of treatment ended Feb 24, 1996
Stopped Course of treatment ended Dec 26, 1996
Stopped Course of treatment ended Jul 20, 1997
Stopped Course of treatment ended Dec 20, 1997
Stopped Course of treatment ended Apr 20, 1998
Stopped Course of treatment ended Dec 04, 1998
Stopped Course of treatment ended and Did not seem to work Aug 03, 2003
Stopped Did not seem to work Sep 03, 2003
Stopped Did not seem to work Oct 03, 2003
Stopped Did not seem to work Nov 03, 2003
Stopped Did not seem to work Dec 03, 2003
Evaluations

About Solu-Medrol (Prescription Drug)

Solu-MedrolĀ® is a brand name for methylprednisolone sodium succinate for IV or IM admininstration. It is used as an anti-inflammatory or immunosuppressant agent for diseases of hematologic, allergic, inflammatory, neoplastic, and autoimmune origin; also for graft-versus-host disease.

Learn more about Solu-Medrol in our Solu-Medrol Community Report.